This was the stock's fourth consecutive day of losses.

HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

According to Benzinga Pro, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which ...

The 26-year-old breakout, aka the Midwest Princess, will take the stage in West Hollywood on March 2. The fundraiser will be co-hosted by Jean Smart, Sheryl Lee Ralph, Neil Patrick Harris and David ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report). The company’s ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

A decrease in California's sexually transmitted infections (STIs) followed early real-world adoption of doxycycline ...

This was the stock's third consecutive day of losses.

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...